tetano
Editor, Senior Moderator
Healthcare (Basel)
. 2021 Dec 27;10(1):42.
doi: 10.3390/healthcare10010042.
Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
Danny H Pham[SUP] 1 [/SUP], Sandy Wong[SUP] 2 [/SUP], Christina T Nguyen[SUP] 2 3 [/SUP], Stephen C Lee[SUP] 1 [/SUP], Kimberly J Won[SUP] 2 3 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion to ambulatory patients with mild or moderate COVID-19, but a concern that arose was deciding the optimal location for patients to receive the medication. This report describes the development and implementation of a bamlanivimab infusion center in the emergency department of three hospitals in Orange County, California, shortly after bamlanivimab received emergency use authorization. As a result, a total of 601 patients received bamlanivimab in one of these three emergency departments between December 2020 to April 2021. The emergency department was shown to be an optimal setting for administration of bamlanivimab due to its convenience, accessibility, and capabilities for monitoring patients.
Keywords: bamlanivimab; coronavirus; emergency department infusion center.
. 2021 Dec 27;10(1):42.
doi: 10.3390/healthcare10010042.
Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
Danny H Pham[SUP] 1 [/SUP], Sandy Wong[SUP] 2 [/SUP], Christina T Nguyen[SUP] 2 3 [/SUP], Stephen C Lee[SUP] 1 [/SUP], Kimberly J Won[SUP] 2 3 [/SUP]
Affiliations
- PMID: 35052205
- DOI: 10.3390/healthcare10010042
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion to ambulatory patients with mild or moderate COVID-19, but a concern that arose was deciding the optimal location for patients to receive the medication. This report describes the development and implementation of a bamlanivimab infusion center in the emergency department of three hospitals in Orange County, California, shortly after bamlanivimab received emergency use authorization. As a result, a total of 601 patients received bamlanivimab in one of these three emergency departments between December 2020 to April 2021. The emergency department was shown to be an optimal setting for administration of bamlanivimab due to its convenience, accessibility, and capabilities for monitoring patients.
Keywords: bamlanivimab; coronavirus; emergency department infusion center.